Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
IFOM ETS - The AIRC Institute of Molecular Oncology
Merck Sharp & Dohme LLC
University of Pittsburgh
National Cancer Centre, Singapore
Eisai Inc.
Sanofi
Merck Sharp & Dohme LLC
Tempest Therapeutics
Xencor, Inc.
Incyte Corporation
Trishula Therapeutics, Inc.
Karyopharm Therapeutics Inc
University of California, San Francisco
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sellas Life Sciences Group
Eli Lilly and Company
Merck Sharp & Dohme LLC
University of Colorado, Denver
Celldex Therapeutics
Corvus Pharmaceuticals, Inc.
Emory University
Merck Sharp & Dohme LLC
Fate Therapeutics
Xencor, Inc.
Roswell Park Cancer Institute
Incyte Corporation
University Hospital Heidelberg
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
Hoosier Cancer Research Network
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gary Onik MD
TME Pharma AG
University of Pittsburgh